CONDITIONS WE TREAT
Mycotoxin illness and environmental toxin exposure trigger a cascade of immune, neurological, and metabolic disruptions. SynergyO3 investigates the root biological mechanisms — oxidative stress, immune dysregulation, and impaired detoxification — to design a physician-supervised recovery protocol.
CLINICAL PRESENTATION
Mold and environmental toxin illness presents across multiple body systems simultaneously. Symptoms are often dismissed or misdiagnosed. Individual results vary — Dr. Volpp evaluates each patient's complete clinical picture.
Symptoms often emerge weeks to months after sustained exposure to water-damaged buildings, mycotoxins, or environmental chemicals. Many patients cycle through multiple diagnoses before the toxic exposure link is identified.
Lab findings may include elevated C4a, TGF-β1, and MMP-9 (Shoemaker panel), reduced MSH (melanocyte-stimulating hormone), abnormal ADH/osmolality, elevated mycotoxin levels on urine testing, and disrupted HPA axis markers.
COMMONLY OVERLAPPING CONDITIONS
CLINICAL EDUCATION
Mycotoxins produced by mold species such as Stachybotrys, Aspergillus, and Penicillium are potent biotoxins that impair mitochondrial function, trigger chronic immune activation, and disrupt the HPA axis. Individual biological susceptibility is influenced by HLA-DR gene variants that affect biotoxin clearance.
Approximately 24% of the population carries HLA-DR variants that impair biotoxin clearance. These individuals cannot effectively eliminate mycotoxins through normal pathways, leading to biotoxin recirculation and sustained systemic inflammation.
Mycotoxins cross the blood-brain barrier and activate microglial cells, releasing matrix metalloproteinase-9 (MMP-9). Elevated MMP-9 damages the blood-brain barrier further, perpetuating neurological symptoms including brain fog, anxiety, and cognitive impairment.
Chronic biotoxin exposure suppresses melanocyte-stimulating hormone (MSH), a master regulatory peptide controlling inflammation, sleep architecture, and mucosal immunity. Low MSH perpetuates the inflammatory cascade and increases susceptibility to opportunistic infections.
KEY STATISTICS
Comprehensive intake, targeted labs, and biomarker assessment to map biological drivers.
Physician-designed sequenced protocol combining EBOO, HOCATT, and IV nutrients.
Follow-up labs, functional benchmarks, and protocol refinement based on response.
ROOT CAUSE INVESTIGATION
Dr. Volpp evaluates each patient's complete picture — identifying which biological mechanisms are most active — before any protocol is designed. Individual results vary.
HLA-DR gene variants prevent normal mycotoxin elimination. Biotoxins recirculate through the enterohepatic pathway, maintaining a continuous inflammatory signal that drives symptoms.
Mycotoxins directly inhibit mitochondrial respiration, reduce glutathione reserves, and generate reactive oxygen species — depleting cellular energy production and driving systemic fatigue and pain.
Chronic biotoxin exposure shifts immune balance toward a Th2-dominant state, elevating pro-inflammatory cytokines including TGF-β1, C4a, and TNF-α while suppressing regulatory T-cell function.
TREATMENT APPROACH
All protocols are physician-designed and supervised by Dr. Heather Volpp, MD. Therapies are selected based on each patient's evaluation. Results may vary.
EBOO ozone therapy may support biotoxin clearance by upregulating antioxidant enzyme systems (superoxide dismutase, catalase, glutathione peroxidase), reducing oxidative burden, and supporting mitochondrial function impaired by mycotoxin exposure.
The HOCATT combines ozone steam, carbonic acid, far-infrared, and full-spectrum light. May support lymphatic drainage of biotoxins, stimulate heat shock proteins, and activate the autonomic nervous system.
YOUR PATH FORWARD
Every patient begins with a comprehensive physician evaluation. No protocol begins before Dr. Volpp has reviewed your complete clinical picture.
A comprehensive intake with Dr. Volpp reviewing your symptom timeline, prior lab work, medications, and functional status. Targeted lab panels are ordered to identify active biological drivers.
Based on your evaluation findings, Dr. Volpp designs a sequenced treatment protocol — typically combining EBOO sessions, HOCATT therapy, and IV nutrient support at clinically appropriate intervals.
Functional benchmarks and symptom tracking guide protocol adjustments. Follow-up labs assess inflammatory markers and key biomarkers. Treatment frequency is adjusted as you progress toward your goals.
COMMON QUESTIONS
TAKE THE NEXT STEP
Begin with a comprehensive consultation with Dr. Heather Volpp, MD — Board-Certified Internal Medicine. Your evaluation will review your full clinical picture and identify which biological mechanisms may be driving your symptoms.
Book Your Appointment →Physician-Supervised · SynergyO3 Medical · Encinitas, CA · (760) 450-4602
Individual results vary. Consult with Dr. Volpp during your evaluation.
